Allogene Therapeutics reports first clinical data from Phase 1 RESOLUTION study of ALLO-329 in autoimmune disease
ALLO•Allogene Therapeutics reported first clinical data from its Phase 1 RESOLUTION study of ALLO-329 in autoimmune disease. The company said 22% of patients experienced grade 1 or 2 cytokine release syndrome, and no patients in the no-lymphodepletion cohorts had treatment-emergent adverse events above grade 2.
1. Early safety data
Allogene Therapeutics said ALLO-329 showed a favorable early safety profile in the Phase 1 study. Cytokine release syndrome occurred in 22% of patients, all at grade 1 or 2; no patients in the no-LD cohorts experienced treatment-emergent adverse events greater than grade 2.
